Spatial transcriptomics company Vizgen closed a $48 million financing led by Arch Venture Partners, M Ventures and Northpond to accelerate commercial growth and push toward profitability. CEO Rob Carson said funds will scale operations, shorten turnaround times, expand consumables and prepare a broader sales and software push tied to MERFISH 2.0 chemistry and proteomics expansions. Vizgen framed the raise as positioning the company to compete in a crowded spatial biology market—Illumina, 10x and others are advancing competing offerings. The company emphasized consumables, software and global field teams as keys to commercial traction. The financing underscores investor appetite for tools enabling multiomic spatial profiling, a capability pharma uses to map tumor microenvironments and stratify patients in discovery and translational programs.